RxDoctor Payments Data

Amanda Gill, NP

Family · Vicksburg, MSNPI 1598230245

Payments from drug & device makers

$2,353in general payments, 2019–2025

Across 153 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$889
  • Mylan Specialty L.p.$159
  • Merck$130
  • Viiv Healthcare Company$113
  • Lundbeck LLC$105
  • Novartis$84
  • plus $873 from 28 others

What the payments were for

  • Food & beverage$2,353100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,353 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$97,020
Medicare patients
273
Services billed
2,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala48$217,964
DalvanceDalbavancin Hcl26$137,536
VabomereMeropenem/Vaborbactam18$83,469
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$48,675
JulucaDolutegravir/Rilpivirine13$42,762
OzempicSemaglutide29$27,645
TrulicityDulaglutide11$20,651
MounjaroTirzepatide18$20,402
LinzessLinaclotide17$15,194
ErtapenemErtapenem Sodium39$14,459
Fosfomycin Tromethamine19$5,155
Breo ElliptaFluticasone/Vilanterol11$4,769
Incruse ElliptaUmeclidinium Bromide12$4,531
MicafunginMicafungin Sodium11$3,425
Diclofenac Sodium21$1,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$56$217,96448 claims
AbbVieDalvance, Linzess$889$152,73043 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$66$57,97565 claims
Viiv Healthcare CompanyJuluca$113$42,76213 claims
Lilly USA, LLCTrulicity, Mounjaro$29$41,05329 claims
Novo NordiskOzempic$68$27,64529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.

Other family in Vicksburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →